2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
The 2022 ESC/ERS guideline lowered the haemodynamic definition of pulmonary hypertension (mean PAP >20 mmHg) and structures pulmonary-arterial-hypertension (PAH) treatment around risk-based, upfront combination therapy. The register's landmark PAH drug trials are listed below.
This guideline cites 2 of the 199 landmark trials in our Cardiology register.
Source
Humbert M, Kovacs G, et al. Eur Heart J. 2022;43(38):3618–3731. · European Heart Journal